K Raghavendra Rao, chairman and MD of Orchid Chemicals and Pharma, says weakening of rupee had a positive impact on margins besides the product mix and contractual supplies. He expects the company to achieve 95 per cent of guidance for FY12 with EBITDA and profit levels exceeding the guidance.
